INTENSITY THERAPEUTICS, INC. (INTS)

Import this data to Google Sheets with:

=jivedata("INTS","financials")

Full statements spill as a table. For one cell: =jivedata("INTS","Revenue") or =jivedata("INTS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

INTENSITY THERAPEUTICS, INC.

INTS • CIK 0001567264

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$4,786	$10,496	$6,785	$6,083
General and Administrative Expense	$3,533	$6,089	$5,187	$5,400
Operating Expenses	$8,319	$16,585	$11,972	$11,483
Net Income (Loss) Attributable to Parent	$-10,538	$-16,268	$-11,606	$-11,163
Operating Income (Loss)	$-8,319	$-16,585	$-11,972	$-11,483
Weighted Average Number of Shares Outstanding, Basic	8,616,324	13,906,973	1,356,358	-13,053,769
Investment Income, Interest	$324	$314	$180	$318
Other Nonoperating Income (Expense)	—	—	$186	$2
Share-based Payment Arrangement, Expense	$1,398	$3,073	$2,000	$1,695

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$8,556	$2,590	$11,921	$9,529
Prepaid Expense and Other Assets, Current	—	$773	$788	$1,700
Operating Lease, Right-of-Use Asset	$147	$122	$96	$82
Assets, Current	$15,464	$3,363	$12,709	$11,229
Other Assets, Noncurrent	$1,684	$1,298	$1,296	$210
Assets	$17,295	$4,783	$14,101	$11,521
Operating Lease, Liability, Noncurrent	$138	$110	$79	$62
Liabilities	$4,133	$1,865	$2,225	$2,307
Accounts Payable, Current	$3,048	$1,219	$583	$1,009
Accrued Liabilities, Current	$891	$508	$1,532	$1,203
Operating Lease, Liability, Current	$20	$28	$31	$33
Liabilities, Current	$3,959	$1,755	$2,146	$2,245
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$1	$2	$0	$0
Additional Paid in Capital	$63,676	$69,699	$90,265	$93,044
Retained Earnings (Accumulated Deficit)	$-50,515	$-66,783	$-78,389	$-83,830
Stockholders' Equity Attributable to Parent	$13,162	$2,918	$11,876	$9,214
Preferred Stock, Shares Authorized	15,000,000	15,000,000	15,000,000	15,000,000
Preferred Stock, Shares Issued	—	0	0	0
Common Stock, Shares Authorized	135,000,000	135,000,000	135,000,000	135,000,000
Common Stock, Shares, Issued	13,709,377	15,122,873	2,524,475	2,945,552
Operating Lease, Liability	$158	$138	$110	$95

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$7,244	$-5,966	$9,331	$7,313
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$8,556	$2,590	$11,921	$21,237
Net Income (Loss) Attributable to Parent	$-10,538	$-16,268	$-11,606	$-11,163
Net Cash Provided by (Used in) Operating Activities	$-7,205	$-15,220	$-9,233	$-8,954
Payments to Acquire Debt Securities, Available-for-sale	$15,053	$3,056	$0	$0
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$9,030	$9,410	$0	$0
Net Cash Provided by (Used in) Investing Activities	$-6,023	$6,354	$0	$0
Proceeds from Issuance Initial Public Offering	$22,425	$0	$4,652	$0
Payments of Stock Issuance Costs	$2,233	—	—	—
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	$50	$321	$56	$56
Net Cash Provided by (Used in) Financing Activities	$20,472	$2,900	$18,564	$16,267
Stock Issued	$4,737	$0	$0	$231
Operating Lease, Right-of-Use Asset, Amortization Expense	$147	$25	$26	$27
Share-based Payment Arrangement, Noncash Expense	$1,398	$3,073	$2,000	$1,695
Increase (Decrease) in Accrued Interest Receivable, Net	$197	$134	$0	$0
Increase (Decrease) in Prepaid Expense and Other Assets	$2,067	$-301	$13	$-208
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$1,631	$-2,268	$360	$279

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("INTS","financials")

Full statements spill as a table. For one cell: =jivedata("INTS","Revenue") or =jivedata("INTS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.